Article Text

PDF
New advances in the management of juvenile idiopathic arthritis—2: The era of biologicals
  1. M W Beresford1,
  2. E M Baildam2
  1. 1
    Institute of Child Health, Alder Hey Children's NHS Foundation Trust, University of Liverpool, Liverpool, UK
  2. 2
    Department of Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
  1. Correspondence to Dr Michael W Beresford, Institute of Child Health, University of Liverpool, Alder Hey Children's NHS Foundation Trust, Eaton Road, Liverpool L12 2AP, UK; m.w.beresford{at}liverpool.ac.uk

Abstract

Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatic disease with significant long-term morbidity and mortality. Major advances have taken place in recent years in our understanding and the evidence base of JIA.

The advent of biological therapies has opened a major new era in the medical management of JIA with recent trials published of etanercept, infliximab, adalimumab, abatacept, tocilizumab and anakinra.

National and international collaborative clinical and research networks are ideally placed to enable future advances in the management of JIA and all paediatric rheumatic disorders.

This review follows on from Part 1 of a review of recent advances in non-biological therapies in JIA, and focuses on the significant new advances in biological therapies in managing JIA.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and Peer review Commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.